What does this research mean for the field?

The Bi-targeted Tumor-Associated Cytotoxicity (BiTAC) T cell engager platform, utilizing an AND-gated split-binder mechanism, selectively eliminates solid tumor cells co-expressing two specific antigens while sparing healthy tissue, demonstrating strong preclinical antitumor efficacy. Novelty: ClaimNovelty.METHODOLOGICAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To develop a dual-targeting T cell engager that selectively kills solid tumor cells while sparing healthy cells.

April 5, 2026Cancer Research

Abstract 1634: A conditionally-active, dual-targeting TCE with superior tumor selectivity for the treatment of solid tumors

View Full Paper

Ask AI

Bookmark

Authors

SDSteffen Dickopf JRJorge A. Lerma Romero JSJessica Seib

Discussion

Member takes

Overview

Novel T cell engagers demonstrate improved tumor selectivity in solid tumors, suggesting enhanced therapeutic potential.

Key Points

To develop a dual-targeting T cell engager that selectively kills solid tumor cells while sparing healthy cells.
Developed an AND-gated safety mechanism with Bi-targeted Tumor-Associated Cytotoxicity (BiTAC) platform
Utilized an on-cell assembly of two complementary compounds targeting distinct tumor-associated antigens
Conducted in vitro T cell-dependent cellular cytotoxicity assays across multiple cell lines in 2D and 3D cultures
Assessed efficacy in PBMC-engrafted mice with colorectal tumors
Analyzed the pharmacokinetics in preclinical mouse studies.
Identified a tumor-associated antigen pair co-expressed in colorectal and lung cancers
Demonstrated selective elimination of dual-target-positive tumor cells in vitro and in vivo
Confirmed strong antitumor efficacy and favorable pharmacokinetic profile in preclinical models

Cite This Study

Dickopf et al. (2026) studied this question.

synapsesocial.com/papers/69d1fe07a79560c99a0a46c7 https://doi.org/10.1158/1538-7445.am2026-1634

View Full Paper

Ask AI

Bookmark

April 5, 2026Cancer Research

Abstract 1634: A conditionally-active, dual-targeting TCE with superior tumor selectivity for the treatment of solid tumors

View Full Paper

Ask AI

Bookmark

Authors

SDSteffen Dickopf JRJorge A. Lerma Romero JSJessica Seib

Discussion

Member takes

Overview

Novel T cell engagers demonstrate improved tumor selectivity in solid tumors, suggesting enhanced therapeutic potential.

Key Points

To develop a dual-targeting T cell engager that selectively kills solid tumor cells while sparing healthy cells.
Developed an AND-gated safety mechanism with Bi-targeted Tumor-Associated Cytotoxicity (BiTAC) platform
Utilized an on-cell assembly of two complementary compounds targeting distinct tumor-associated antigens
Conducted in vitro T cell-dependent cellular cytotoxicity assays across multiple cell lines in 2D and 3D cultures
Assessed efficacy in PBMC-engrafted mice with colorectal tumors
Analyzed the pharmacokinetics in preclinical mouse studies.
Identified a tumor-associated antigen pair co-expressed in colorectal and lung cancers
Demonstrated selective elimination of dual-target-positive tumor cells in vitro and in vivo
Confirmed strong antitumor efficacy and favorable pharmacokinetic profile in preclinical models

Cite This Study

Dickopf et al. (2026) studied this question.

synapsesocial.com/papers/69d1fe07a79560c99a0a46c7 https://doi.org/10.1158/1538-7445.am2026-1634

View Full Paper

Ask AI

Bookmark